Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 21, 2026

Liven AS - 2026. aasta I kvartali konsolideeritud auditeerimata vahearuanne

View original at globenewswire.com
“Raha ja raha ekvivalendid [Cash and cash equivalents] 8 054 [as of 31.03.2026, in thousands of euros per table header '(tuhandeteseurodes)']”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Instead of the typically quieter start to the year, the activity from the end of the previous year continued into Q1, and we doubled last year's sales results

    60% confidence
  • European Central Bank forecasts inflation for 2026-2028 at 2.6%, 2.0%, and 2.1% respectively, which rather indicates long-term monetary policy stability

    60% confidence
  • We consider it realistic to realize approximately 2/3 of the possible volume, which means delivering more than 190 homes and approximately 20% revenue growth to close to 59 million euros

    60% confidence
  • We expect construction loan volumes to grow until mid-2026 due to ongoing construction works

    60% confidence
  • According to Bank of Estonia forecast, 2026 inflation will be approximately 3.8% due to production costs, tax increases and continued wage growth

    60% confidence
  • Customer satisfaction feedback collected at different stages of the customer journey remained stable at a high level of 9.6 points out of 10 for the last 12 months

    60% confidence
  • In our existing land portfolio there is work for continuing years, but we see opportunities in the market to acquire new properties that would allow us to significantly increase supply and revenue volumes in the long term

    60% confidence
  • We continue active negotiations for acquiring properties both in Tallinn and Berlin, as well as preparations for the initial public offering of shares and listing on the Nasdaq Tallinn main list

    60% confidence
  • Despite external environment pressure, demand for new homes remained strong both at the end of Q1 and after the quarter end, and current consumer behavior in the market does not give reason to correct previously set forecasts today

    60% confidence
  • Together with revenue growth, we expect profit growth and exceeding the 20% return on equity target

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com